Nanjing Leads Biolabs Co., Ltd. Class H 9887

NANJING, China, Sept. 28, 2026 (GLOBE NEWSWIRE) -- Nanjing Leads Biolabs Co., Ltd. (“Leads Biolabs” or the “Company,” Stock Code: 9887.HK) today announced that opamtistomig (LBL-024), the Company’s proprietary PD‑L1/4‑1BB bispecific antibody, has been granted Orphan Drug Designation (ODD) by Japan’s Ministry of Health, Labour and Welfare (MHLW) for the treatment of extrapulmonary neuroendocrine carcinoma (EP-NEC). This is the third Orphan Drug Designation for opamtistomig, following designations

NANJING, China, Sept. 21, 2026 (GLOBE NEWSWIRE) -- Nanjing Leads Biolabs Co., Ltd. (“Leads Biolabs” or the “Company,” Stock Code: 9887.HK) today announced that its pivotal registrational Phase IIb study of opamtistomig (LBL-024), the Company’s proprietary PD-L1/4-1BB bispecific antibody, as monotherapy for patients with advanced extrapulmonary neuroendocrine carcinoma (EP-NEC), has been selected as a Late-Breaking Abstract (LBA) and Proffered Paper presentation at the ESMO Congress 2026. The sel

NANJING, China, Sept. 14, 2026 (GLOBE NEWSWIRE) -- Nanjing Leads Biolabs Co., Ltd. (“Leads Biolabs” or the “Company,” Stock Code: 9887.HK) today announced that updated Phase II data for opamtistomig (LBL-024), its proprietary PD-L1/4-1BB bispecific antibody, plus chemotherapy as first-line treatment for non-small cell lung cancer (NSCLC), were presented in an oral presentation at the 2026 World Conference on Lung Cancer (WCLC). The updated data demonstrated robust and durable antitumor activity

Nanjing Leads Biolabs (SEHK:9887) reported that China's National Medical Products Administration accepted its NDA for Opamtistomig as a first in class PD-L1/4-1BB bispecific antibody for extrapulmonary neuroendocrine carcinoma. The company highlighted that, if approved, Opamtistomig could become the world's first approved antibody directly targeting 4-1BB. Nanjing Leads Biolabs also advanced Opamtistomig into key expansion phases in multiple clinical trials for esophageal squamous cell...

NANJING, China, Aug. 24, 2026 (GLOBE NEWSWIRE) -- Nanjing Leads Biolabs Co., Ltd. (“Leads Biolabs” or the “Company,” Stock Code: 9887.HK) today announced that Opamtistomig (LBL-024), the Company’s proprietary PD-L1/4-1BB bispecific antibody, as a first-line treatment for locally advanced or metastatic esophageal squamous cell carcinoma (ESCC), has completed its safety run‑in assessment and advanced to the expansion phase based on encouraging efficacy signals and a favorable safety profile. The s

Nanjing Leads Biolabs Co., Ltd. ("Leads Biolabs" or the "Company," Stock Code: 9887.HK) today announced the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) has accepted the New Drug Application (NDA) for Opamtistomig (LBL-024), the Company's proprietary PD-L1/4-1BB bispecific antibody, as a monotherapy for the treatment of previously treated advanced extrapulmonary neuroendocrine carcinoma (EP-NEC).

NANJING, China, Aug. 20, 2026 (GLOBE NEWSWIRE) -- Nanjing Leads Biolabs Co., Ltd. (“Leads Biolabs” or the “Company,” Stock Code: 9887.HK) today announced that the full abstract of the Phase II clinical study evaluating its proprietary drug candidate LBL-024 (Opamtistomig, a PD-L1/4-1BB bispecific antibody) in combination with chemotherapy as a first-line treatment for non-small cell lung cancer (“NSCLC”) has been published on the official website of the World Conference on Lung Cancer (the “WCLC

NANJING, China, Aug. 05, 2026 (GLOBE NEWSWIRE) -- Nanjing Leads Biolabs Co., Ltd. (“Leads Biolabs” or the “Company,” Stock Code: 9887.HK) today announced that its Phase II clinical study evaluating Opamtistomig (LBL-024), a proprietary PD-L1/4-1BB bispecific antibody, in combination with bevacizumab for the treatment of first-line hepatocellular carcinoma (HCC) has successfully completed the safety run-in phase assessment following expert review and has advanced into the expansion phase. The stu

-- First‑in‑human trial of Oblenio’s sole asset, a CD19×BCMA×CD3 tri‑specific T‑cell engager, moves forward to rapidly generate broad proof of concept --NANJING, China, Aug. 04, 2026 (GLOBE NEWSWIRE) -- Nanjing Leads Biolabs Co., Ltd. (“Leads Biolabs” or the “Company,” Stock Code: 9887.HK) today announced that its partner company with Aditum Bio, Oblenio Bio (“Oblenio”), has dosed first patients in the Phase 1a first‑in‑human clinical trial in Europe of its sole asset LBL‑051, a tri‑specific T‑c

NANJING, China, Aug. 02, 2026 (GLOBE NEWSWIRE) -- Nanjing Leads Biolabs Co., Ltd. (“Leads Biolabs” or the “Company,” Stock Code: 9887.HK) today announced that the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) has approved the investigational new drug (IND) application for an open-label, multicenter Phase Ib/II clinical trial of its proprietary PD-L1/4-1BB bispecific antibody, Opamtistomig (LBL-024), in combination therapy for metastatic colorectal cancer

NANJING, China, July 30, 2026 (GLOBE NEWSWIRE) -- Nanjing Leads Biolabs Co., Ltd. (“Leads Biolabs” or the “Company,” Stock Code: 9887.HK) announced that the Phase II clinical study of its core product Opamtistomig (LBL-024, a PD-L1/4-1BB bispecific antibody) for the treatment of first-line advanced biliary tract cancer (BTC) has completed enrollment of all 70 patients. In April 2026, the study successfully entered the expansion phase based on a favorable safety profile and robust efficacy that e

Nanjing Leads Biolabs Co., Ltd. ("Leads Biolabs" or the "Company," Stock Code: 9887.HK) today announced that six of its latest research studies have been accepted for presentation at the 2026 European Society for Medical Oncology (ESMO) Annual Congress. Among these, two have been selected as Proffered Papers—the congress's highest-profile oral presentation format, while four will be presented as posters, covering multiple tumor types such as extrapulmonary neuroendocrine carcinoma (EP‑NEC), bili

Nanjing Leads Biolabs Co., Ltd. ("Leads Biolabs" or the "Company," Stock Code: 9887.HK) today announced that the biologics license application (BLA) for Opamtistomig (LBL-024, a PD-L1/4-1BB bispecific antibody) as monotherapy for the treatment of advanced extrapulmonary neuroendocrine carcinoma (EP-NEC) has been approved by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) of the People's Republic of China for inclusion in the priority review and approva

NANJING, China, June 25, 2026 (GLOBE NEWSWIRE) -- Nanjing Leads Biolabs Co., Ltd. (“Leads Biolabs” or the “Company,” Stock Code: 9887.HK) today announced that its partner company with Aditum Bio, Oblenio Bio (“Oblenio”), has successfully closed an oversubscribed $62 million Series B financing round. The round was led by Pfizer Ventures, with participation from Deep Track Capital, GV, and founding investor Aditum Bio. This milestone significantly advances the clinical development of LBL‑051, Oble

Nanjing Leads Biolabs Co., Ltd. ("Leads Biolabs" or the "Company," Stock Code: 9887.HK) today announced that the Phase II clinical study of its proprietary PD-L1/4-1BB bispecific antibody, Opamtistomig (LBL-024), in combination with chemotherapy for the first-line treatment of non-small cell lung cancer (NSCLC), has been selected for an oral presentation at the 2026 World Conference on Lung Cancer (WCLC), the world's most influential scientific meeting in the lung cancer field, taking place Sept

Nanjing Leads Biolabs Co., Ltd. ("Leads Biolabs" or the "Company," Stock Code: 9887.HK) today announced that its proprietary PD-L1/4-1BB bispecific antibody, Opamtistomig (LBL-024), has received approval from the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) to initiate a pivotal Phase III clinical trial for the first-line treatment of advanced extrapulmonary neuroendocrine carcinoma (EP-NEC). This approval marks the successful advancement of Opamtis

Dianthus Therapeutics (DNTH) is in focus after updating investors on LBL-047, its lead autoimmune asset, including new priority indications, partnership terms with Leads Biolabs, and funding raised to support clinical development. See our latest analysis for Dianthus Therapeutics. The recent update on LBL-047 and the earlier financing round come after a very strong run. The latest share price is $86.16, with a 90 day share price return of 75.09% and a 1 year total shareholder return of about...

Recent share performance and business snapshot Nanjing Leads Biolabs (SEHK:9887) has seen its share price fall 8% over the past day and 12% over the past week. This has added short term volatility to a stock that is still up over the past 3 months and year to date. At a last close of HK$69.40 and a market value of about HK$13.8b, the clinical stage biotechnology company is focused on antibody drugs for oncology, autoimmune and other severe diseases. Its work is supported by several platforms...